Skip to main content

Physician Search

 


Displaying 1 - 1 of 1

First-in-human Study of DRP-104 (Sirpiglenastat) as Single Agent and in Combination With Atezolizumab in Patients With Advanced Solid Tumors.

Phase I

The purpose of this study is to characterize the safety, tolerability, pharmacokinetics,
pharmaco-dynamics and preliminary anti-tumor activity of DRP-104 (sirpiglenastat)
administered via intravenous infusion or via subcutaneous injection as a single agent and in
combination with atezolizumab in patients with advanced solid tumors and to assess
preliminary safety and efficacy of which route of administration (intravenous or
subcutaneous) will be selected for further development for the other two expansions of
patients, advanced non-small cell lung cancer (NSCLC) with defined genetic mutations, and
advanced squamous cell carcinoma of the head and neck (SCCHN).
Phase I
I/II
Gibson, Mike
NCT04471415
VICCPHI2050